Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191188 | 0.86 | MAOA (0.47) | MAOASMN1; SMN2GAANPSR1KMT2A | |
| SCHEMBL29952699 | 0.86 | KMT2A (0.43) | MAOASMN1; SMN2GAANPSR1KMT2A | |
| SCHEMBL19002619 | 0.86 | EPHX2 (0.46) | MAOASMN1; SMN2GAANPSR1KMT2A | |
| SCHEMBL19002495 | 0.83 | EPHX2 (0.47) | MAOASMN1; SMN2GAANPSR1KMT2A | |
| SCHEMBL10132042 | 0.83 | MAOA (0.40) | MAOASMN1; SMN2GAANPSR1KMT2A | |
| SCHEMBL19049412 | 0.83 | EPHX2 (0.43) | MAOASMN1; SMN2GAANPSR1KMT2A | |
| SCHEMBL29952336 | 0.82 | LMNA (0.40) | MAOASMN1; SMN2GAANPSR1KMT2A | |
| SCHEMBL23222183 | 0.82 | EPHX2 (0.42) | MAOASMN1; SMN2GAANPSR1KMT2A | |
| SCHEMBL19002620 | 0.82 | EPHX2 (0.42) | MAOASMN1; SMN2GAANPSR1KMT2A | |
| SCHEMBL854305 | 0.80 | MAOA (0.42) | MAOASMN1; SMN2GAANPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101186-B2 | Peptides that block the binding of IgG to FcRn | SYNTONIX PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | MAOA 3581/4885SMN1; SMN2 4722/4885GAA 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.